Tactile Systems Technology, Inc. (TCMD)

Over the past six months, TCMD's stock price has been influenced by several events. Tactile Medical reported strong fourth-quarter 2025 and first-quarter 2026 financial results, with revenue increases. Management raised its full-year 2026 revenue guidance. Tactile Systems Technology closed the acquisition of LymphaTech, Inc. New Medicare prior authorization requirements for pneumatic compression devices have been noted as a potential near-term headwind. As of May 9, 2026, TCMD shares have decreased by 11.6% since the beginning of 2026, but increased by 64.20% over the past year. Insiders have sold more company stock than they have bought, with total insider sales of approximately $1.43 million.

Demand for Tactile Systems Technology's products and services exhibits seasonality. The first quarter is historically the company's weakest seasonal period. The company tends to experience its strongest performance in the second half of the year, particularly in the third quarter. Management anticipates that quarterly ordering patterns will normalize once the new Medicare prior authorization process settles.

Tactile Systems Technology, Inc. (TCMD) is a medical technology company focused on developing and providing medical devices for underserved chronic diseases, primarily in the United States. The company's main product offerings include the Flexitouch Plus system, a pneumatic compression device for treating lymphedema and related conditions; the Entre Plus System, another pneumatic compression device for at-home treatment; Nimbl, a pneumatic compression platform for upper extremity lymphedema; Kylee, a mobile application for lymphedema patient support; and AffloVest, a portable high-frequency chest wall oscillation vest for patients with retained pulmonary secretions. The company also received FDA 510(k) clearance for a next-generation AffloVest device.

Tactile Systems Technology, Inc. is headquartered in Minneapolis, Minnesota. The company primarily operates in the United States, with select distribution partnerships extending to Canada and other international markets.

Tactile Systems Technology has maintained a generally positive brand reputation. A study demonstrated sustained clinical benefits of the Flexitouch Plus system. Analysts have a consensus rating of "Moderate Buy" for Tactile Systems Technology, with an average 12-month price target of $38.60.

Tactile Systems Technology (TCMD) has a mixed ownership structure. Institutions hold a significant portion of the company's shares, with approximately 83.43% of the stock held by institutions. Insiders hold approximately 2.10% to 3.35% of the stock.